While there is interest in applying local therapies to OM and OP breast cancer, the current randomized data does not back the routine use of surgery or SBRT, particularly when considering the potential for treatment-related toxicities. Future research should refine patient selection through advanced imaging and possibly explore these therapies specifically in patients with hormone receptor-positive or HER2-positive disease.
Keyphrases
- current status
- minimally invasive
- double blind
- high resolution
- radiation therapy
- open label
- coronary artery bypass
- phase iii
- placebo controlled
- big data
- randomized controlled trial
- phase ii
- single cell
- clinical trial
- human health
- risk assessment
- young adults
- coronary artery disease
- climate change
- artificial intelligence
- data analysis
- study protocol
- percutaneous coronary intervention